NASDAQ:ACRS Aclaris Therapeutics Q3 2024 Earnings Report $5.50 +0.10 (+1.85%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$5.38 -0.12 (-2.11%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aclaris Therapeutics EPS ResultsActual EPS-$0.11Consensus EPS -$0.08Beat/MissMissed by -$0.03One Year Ago EPSN/AAclaris Therapeutics Revenue ResultsActual Revenue$4.35 millionExpected Revenue$8.31 millionBeat/MissMissed by -$3.96 millionYoY Revenue GrowthN/AAclaris Therapeutics Announcement DetailsQuarterQ3 2024Date11/6/2024TimeBefore Market OpensConference Call DateWednesday, November 6, 2024Conference Call Time7:00AM ETUpcoming EarningsAclaris Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aclaris Therapeutics Earnings HeadlinesCraig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)3 hours ago | theglobeandmail.comAclaris Therapeutics (ACRS): Multiple Catalysts Could Make 2H 2026 A Defining PeriodSeptember 10, 2026 | rttnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 19 at 1:00 AM | Weiss Ratings (Ad)Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.33 Average Price Target from BrokeragesSeptember 10, 2026 | americanbankingnews.comCritical Survey: Whitehawk Therapeutics (NASDAQ:WHWK) vs. Aclaris Therapeutics (NASDAQ:ACRS)September 9, 2026 | americanbankingnews.comAclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comSee More Aclaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email. Email Address About Aclaris TherapeuticsAclaris Therapeutics (NASDAQ:ACRS) (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research programs are centered on potentially addressing conditions in which existing treatments have limited effectiveness or tolerability. Aclaris has developed a pipeline that has included zunsemetinib, an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being studied for inflammatory diseases, and other small-molecule therapies targeting immune and inflammatory pathways. The company has also investigated topical treatments for dermatological conditions, including atopic dermatitis and other skin disorders. Founded in 2012 and headquartered in Wayne, Pennsylvania, Aclaris previously commercialized ESKATA, a topical treatment for raised seborrheic keratoses, before discontinuing the product. The company’s current activities are primarily focused on research, clinical development and advancing its pipeline through clinical testing and potential strategic partnerships.View Aclaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
